Why Is ESSA Pharma Stock Plunging On Friday? - ESSA Pharma ( NASDAQ:EPIX )
On Thursday, ESSA Pharma Inc. EPIX announced its plans to terminate the Phase 2 trial of masofaniten combined with enzalutamide versus enzalutamide single agent in patients with metastatic castration-resistant prostate cancer ( mCRPC ) naïve to second-generation antiandrogens.
| Ticker |
Sentiment |
Impact |
|
EPIX
|
Neutral
|
39 %
|
|
PFE
|
Somewhat Bullish
|
20 %
|
